Shots:
- As per expanded collaboration, PeptiDream to receive ~$3.5B as up front, preclinical, development, launch, and commercial milestones and is eligible to receive royalties on sales of any product that emerges from the collaboration
- The extended collaboration expands the use of the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration & allow Takeda to conjugate the peptides with therapeutic cargoes optimized to cross the BBB
- The companies originally collaborated in Dec’2020 to create PDCs for neuromuscular diseases by conjugating peptides of PeptiDream and JCR that bind to human TfR1 to specific drug payloads selected by Takeda
Click here to read full press release/ article | Ref: Takeda | Image: GeneOnline
The post PeptiDream and Takeda Expand its Research and License Agreement to Develop Peptide Drug Conjugates Targeting CNS Diseases first appeared on PharmaShots.
